Green Cross Corporation operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Green Cross with three other
companies in this sector in KOREA (SOUTH) :
Celltrion HealthCare Co Ltd
sales of 1.10 trillion Korean Won [US$928.04 million]
of which 100%
was Manufacture/Process/Sale of Medicine),
Samsung Biologics Co Ltd
(701.59 billion Korean Won [US$591.44 million]
of which 100%
was Biological Medicine Production), and
(1.13 trillion Korean Won [US$951.29 million]
of which 87%
was Bio Business Division).
Green Cross reported sales of 1.37 trillion Korean Won (US$1.15 billion)
December of 2019.
increase of 2.6%
versus 2018, when the company's sales were 1.33 trillion Korean Won .
Sales at Green Cross have increased during each of the previous five years
(and since 2014, sales have increased a total of 40%).
Sales of Greencross Medis saw an increase
that was more than double the company's growth rate: sales were up
35.5% in 2019, from
7.20 billion Korean Won to 9.75 billion Korean Won .
Green Cross also saw significant increases in sales in
Greencross Ms (up 9.0% to 94.09 billion Korean Won )
Greencrosswb (up 24.2% to 66.94 billion Korean Won )
Greencross Gclabcell (up 9.2% to 55.26 billion Korean Won )
Greencross Genome (up 24.1% to 12.16 billion Korean Won )
Not all segments of Green Cross experienced an increase in sales in 2019:
sales of Invacfarm fell 16.7% to 15.45 billion Korean Won .
(However, this segment's sales were only a very small portion of the company's overall sales).